Evidence map›Paper›PMID 34925640›Full record

ArticleDisease markers2021

CircLDLR Promotes Papillary Thyroid Carcinoma Tumorigenicity by Regulating miR-637/LMO4 Axis.

Yuan-Ming Jiang, Wei Liu, Ling Jiang, Hongbin Chang

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yuan-Ming JiangDepartment of Otolarynology, Wuhan No.1.Hospital, Wuhan 430030, China.ORCID https://orcid.org/0000-0002-9243-1734
Wei LiuDepartment of Otolarynology, Wuhan No.1.Hospital, Wuhan 430030, China.ORCID https://orcid.org/0000-0002-0022-3939
Ling JiangGeneral Surgery, Wuhan Hanyang Hospital, Wuhan 430000, China.ORCID https://orcid.org/0000-0001-7363-3616
Hongbin ChangGeneral Surgery, Wuhan Hanyang Hospital, Wuhan 430000, China.ORCID https://orcid.org/0000-0003-3013-2103
Wuhan General Hospital of Guangzhou · CNWuhan No.1 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) have been reported to play important roles in the development and progression of papillary thyroid carcinoma (PTC). However, the function and molecular mechanism of circRNA low-density lipoprotein receptor (circLDLR) in the tumorigenesis of PTC remain unknown.

resultsIn this study, circLDLR was found to be markedly upregulated in PTC tissues and cell lines, and knockdown of circLDLR inhibited PTC cell proliferation, migration, and invasion but induced apoptosis

conclusionTaken together, these results demonstrated that circLDLR promoted PTC tumorigenesis through miR-637/LMO4 axis, which may provide a novel insight into the understanding of PTC tumorigenesis and be useful in developing potential targets for PTC treatment.

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAnimalsBiomarkers, TumorCarcinogenesisFemaleGene Expression Regulation, NeoplasticHumansLIM Domain ProteinsMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsAdaptor Proteins, Signal TransducingBiomarkers, TumorLDLR protein, humanLIM Domain ProteinsLMO4 protein, humanMicroRNAsMIRN637 microRNA, humanReceptors, LDLRNA, Circular

Identifiers

PMID34925640
PMCPMC8677406
OpenAlexW4200472078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.